Research-Grade Peptides | 99%+ Purity Verified | US Delivery 2–5 Days
Save 5% with Crypto
SaiyanMed

Your Cart

No products in the cart.

CJC-1295 With DAC vs No DAC: Naming, Structure, and Pharmacology Evidence

Conceptual diagram contrasting a documented peptide modification designed for albumin binding with an unresolved molecular identity.

To compare CJC-1295 with DAC vs no DAC, establish the molecular identity first. Jetté and colleagues defined original CJC-1295 as a modified human growth hormone-releasing factor fragment with a C-terminal lysine carrying an N-epsilon-3-maleimidopropionamide group, designed for covalent albumin binding.[1] Here, “with DAC” is the comparison label used in the title, not terminology attributed to that paper. The cited human pharmacology study examined the named CJC-1295 compound; it does not establish the pharmacology of an unspecified no-DAC material.[2]

The original paper describes an albumin-binding modification

Jetté and colleagues described CJC-1295 as a tetrasubstituted derivative of human growth hormone-releasing factor 1–29, or hGRF(1–29), with an added C-terminal lysine bearing an N-epsilon-3-maleimidopropionamide group. The reactive group was designed to enable covalent binding to the free thiol at Cys34 on serum albumin. Their abstract reports cultured rat anterior-pituitary cell and rat experimental findings.[1]

The structural feature relevant to this comparison is that documented albumin-binding modification. A “no DAC” label alone does not establish the material’s complete sequence, terminal chemistry, formulation, or other modifications. The consulted sources do not establish an exact no-DAC structure or verify that “modified GRF(1–29)” is an interchangeable name for a particular no-DAC material.

What the published CJC-1295 PK study actually examined

Evidence-flow schematic connecting a study record to its documented compound while leaving an unidentified material separate.

Pharmacokinetics (PK) concerns the compound’s exposure over time; pharmacodynamics (PD) concerns the measured biological response. Keep the molecular form and experimental system attached to each finding.

Evidence record What the source describes What it does not establish
Jetté et al. (2005) Original CJC-1295’s structural modification and albumin-binding design, with rat cell and animal observations.[1] An exact no-DAC structure or a direct DAC/no-DAC comparison.
Teichman et al. (2006) Two randomized, placebo-controlled, double-blind trials in healthy adults assessing the named CJC-1295 compound. The abstract reports an estimated half-life of 5.8–8.1 days and sustained growth hormone and insulin-like growth factor I measurements.[2] The identity, half-life, or pharmacology of an unspecified no-DAC material.

For example, the 5.8–8.1-day estimate is a reported human-study result for the named CJC-1295 compound, not a general property of everything labeled CJC-1295.[2] If a material is documented only as “CJC-1295 no DAC,” its exact structure and relationship to the study material remain unresolved. The defensible conclusion is that this estimate cannot be assigned to that material from the label alone. These observations are not a treatment recommendation or a demonstration of clinical benefit.

What remains unverified for the no-DAC label

The consulted peer-reviewed records do not establish a specific no-DAC sequence and terminal chemistry, or a direct head-to-head PK comparison between a chemically defined no-DAC form and original CJC-1295. This finding is limited to the source set reviewed for this article; it does not establish that no relevant publication exists elsewhere.

For a specific no-DAC material, exact molecular identity and any claimed comparative PK are not established by the consulted sources; supporting records are needed. A structural source may define a compound, but connecting that definition to a supplied batch also requires material-specific documentation.

Checklist before comparing two materials

Six documentation cards representing sequence, terminal chemistry, modification, formulation, batch-linked analytical results, and study match.

Use the following records to determine whether a material can reasonably be compared with the published compound:

  1. Peptide sequence: obtain the complete sequence and substitutions, with a record defining the claimed structure.
  2. Terminal chemistry: identify the documented N- and C-terminal forms and any terminal groups.
  3. Modification: establish whether the albumin-binding modification described for original CJC-1295 is present and how that assignment is supported.
  4. Formulation and study conditions: record the material form and experimental system used before comparing results.
  5. Batch-linked analytical results: review what the methods actually establish about identity and what remains unresolved. An analytical result supports only the properties its method can assess.
  6. Study match: confirm that the cited paper tested the molecular form being discussed before applying its PK or PD findings to the material.

These are documentation recommendations for evaluating a comparison. The cited papers do not independently validate a particular commercial material or batch.

Related research: CJC-1295 (No DAC); CJC-1295 (with DAC); CJC-1295 No DAC 5mg+ Ipamorelin 5mg.

参考来源

  1. Jetté et al. (2005), “Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog”
  2. Teichman et al. (2006), “Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults”

Research Use Only Disclaimer

This article is for laboratory and analytical research education only. It is not medical or veterinary advice, is not a validated experimental protocol, and provides no instructions for human or animal administration.